These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7510192)

  • 1. Prevention of chemotherapy-induced neutropenia using G-CSF with VACOP-B--a case report.
    Anglin P; Strauss BA; Brandwein JM
    Leuk Lymphoma; 1993 Nov; 11(5-6):469-72. PubMed ID: 7510192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.
    Dotti G; Stella CC; Mangoni L; Cottafavi L; Caramatti C; Almici C; Rizzoli V
    Haematologica; 1995; 80(2):142-5. PubMed ID: 7543069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
    Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
    Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma.
    Zinzani PL; Martelli M; Tura S; Mandelli F
    Haematologica; 1993; 78(1):40-3. PubMed ID: 7684011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease.
    Silvestri F; Fanin R; Velisig M; Barillari G; Virgolini L; Zaja F; Russo D; Baccarani M
    Tumori; 1994 Dec; 80(6):453-8. PubMed ID: 7534963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rhG-CSF on infection complications and impaired function of neutrophils secondary to chemotherapy for non-Hodgkin's lymphoma. Hokkaido Study Group of Malignant Lymphoma, and rhG-CSF, Japan.
    Kuni-Eda Y; Okabe M; Kurosawa M; Maekawa I; Higuchi M; Kawamura M; Morioka M; Suzuki S; Ohmura T; Fujimoto N
    Leuk Lymphoma; 1995 Feb; 16(5-6):471-6. PubMed ID: 7540462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulocyte colony-stimulating factor (G-CSF) allows the delivery of effective doses of CHOP and CVP regimens in non-Hodgkin lymphomas.
    Silvestri F; Velisig M; Fanin R; Virgolini L; Zaja F; Barillari G; Baccarani M
    Leuk Lymphoma; 1995 Feb; 16(5-6):465-70. PubMed ID: 7540461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL).
    Bertini M; Freilone R; Vitolo U; Botto B; Pizzuti M; Gavarotti P; Levis A; Orlandi E; Orsucci L; Pini M
    Ann Oncol; 1994 Dec; 5(10):895-900. PubMed ID: 7535080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
    Santini G; De Souza C; Aversa S; Patti C; Tedeschi L; Candela M; Olivieri A; Chisesi T; Rubagotti A; Centurioni R; Nardi V; Congiu M; Gennaro M; Truini M;
    Braz J Med Biol Res; 2004 May; 37(5):719-28. PubMed ID: 15107935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony stimulating factor (G-CSF) for intermediate-grade non-Hodgkin's lymphoma.
    Niitsu N; Umeda M
    Eur J Haematol; 1996 Mar; 56(3):163-7. PubMed ID: 8598236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The MACOP-B and VACOP-B combination chemotherapy for young patients with intermediate-grade non-Hodgkin's lymphoma.
    Dreiher J; Shpilberg O; Raanani P; Chetrit A; Ben-Bassat I
    Leuk Res; 1998 Nov; 22(11):997-1002. PubMed ID: 9783801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A double-blind, cross-over clinical trial of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
    Oyama A; Ota K; Asano S; Takaku F; Yoshida Y; Uzuka Y; Omine M; Furusawa S; Takatani O; Sawada U
    Nihon Gan Chiryo Gakkai Shi; 1990 Oct; 25(10):2533-48. PubMed ID: 1702132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe neutropenia and relative dose intensity among patients<65 and ≥65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapy.
    Schwartzberg LS; Saleh M; Whittaker S; Abella E
    Support Care Cancer; 2014 Jul; 22(7):1833-41. PubMed ID: 24535242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COP-BLAM regimen combined with granulocyte colony-stimulating factor and high-grade non-Hodgkin's lymphoma.
    Niitsu N; Umeda M
    Eur J Haematol; 1995 Aug; 55(2):88-92. PubMed ID: 7543059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High incidence of chemotherapy-induced acral erythema in female patients with non-Hodgkin's lymphoma treated with the VACOP-B regimen.
    Ogawa H; Sugiyama H; Tani Y; Soma T; Yamagami T; Tatekawa T; Oji Y; Kubota T; Kimura T; Inoue K; Nakagawa M; Sasaki K; Matsunashi T; Miyake S; Kishimoto T
    Leuk Lymphoma; 1998 Mar; 29(1-2):171-7. PubMed ID: 9638986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
    Oyama A; Ota K; Asano S; Takaku F; Miyazaki T; Uzuka Y; Omine M; Furusawa S; Hirashima K; Sanpi K
    Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1619-34. PubMed ID: 1700040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.
    Pettengell R; Gurney H; Radford JA; Deakin DP; James R; Wilkinson PM; Kane K; Bentley J; Crowther D
    Blood; 1992 Sep; 80(6):1430-6. PubMed ID: 1381626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
    Sawka CA; Shepherd FA; Franssen E; Brandwein J; Dotten DA; Routy JP; Walker IR; St-Louis J; Taylor M; Arts K; Crump M; Foote M
    Biotechnol Annu Rev; 2005; 11():381-9. PubMed ID: 16216784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.
    Corato A; Ambrosetti A; Rossi B; Vincenzi C; Lambiase A; Perona G; Pizzolo G; de Wynter E; Nadali G
    J Hematother Stem Cell Res; 2000 Oct; 9(5):673-82. PubMed ID: 11091491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
    Ishii K; Yamamoto Y; Shigeki T; Kitayama H; Hayashi K; Hirose A; Ohta T; Mugitani A; Fujino H; Yagi T; Hirai M; Teshima H; Katsurada T; Urase F; Kitajima H
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):39-44. PubMed ID: 15675580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.